| Multiple Sclerosis, Relapsing-Remitting
Ocrevus vs Ponvory
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, relapsing-remitting.Deep comparison between: Ocrevus vs Ponvory with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPonvory has a higher rate of injection site reactions vs Ocrevus based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ponvory but not Ocrevus, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ocrevus
Ponvory
At A Glance
IV infusion
Every 6 months
CD20 antagonist
Oral
Once daily
S1P receptor 1 modulator
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Primary Progressive
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- active secondary progressive multiple sclerosis
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive Initial dose: 300 mg IV infusion, followed two weeks later by a second 300 mg IV infusion; subsequent doses: 600 mg IV infusion every 6 months.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, active secondary progressive multiple sclerosis Initiate with 14-day oral dose titration starting at 2 mg once daily per schedule; maintenance dose is 20 mg orally once daily beginning Day 15.
Contraindications
- Active HBV infection
- History of life-threatening infusion reaction to OCREVUS
- Myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure within the last 6 months
- Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
Adverse Reactions
Most common (>=10%) Upper respiratory tract infections, infusion reactions, skin infections, lower respiratory tract infections
Serious Infusion reactions, infections, progressive multifocal leukoencephalopathy, reduction in immunoglobulins, malignancies, immune-mediated colitis, liver injury
Postmarketing Immune-mediated colitis, liver injury, serious herpes infections, progressive multifocal leukoencephalopathy, babesiosis, pyoderma gangrenosum
Most common (>=10%) Upper respiratory tract infection, hepatic transaminase elevation, hypertension
Serious Infections, bradyarrhythmia and AV conduction delays, respiratory effects, liver injury, increased blood pressure, cutaneous malignancies, macular edema, posterior reversible encephalopathy syndrome, severe increase in disability after stopping
Pharmacology
CD20 antagonist; ocrelizumab is a recombinant humanized IgG1 monoclonal antibody that binds to CD20 on pre-B and mature B lymphocytes, resulting in antibody-dependent cellular cytolysis and complement-mediated lysis.
Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1 and blocks lymphocyte egress from lymph nodes, reducing peripheral blood lymphocyte counts; the therapeutic mechanism in multiple sclerosis may involve reduction of lymphocyte migration into the central nervous system.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ocrevus
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Ponvory
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (10/12)
UnitedHealthcare
Ocrevus
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Ponvory
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Ocrevus
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Ponvory
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OcrevusView full Ocrevus profile
PonvoryView full Ponvory profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.